Captor Therapeutics - Public Comps and Valuation Multiples

Captor Therapeutics Overview

About Captor Therapeutics

Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Founded

HQ

Employees

n/a

Website

captortherapeutics.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $5.4M

LTM EBITDA -$9.4M

EV

$101M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Captor Therapeutics Financials

As of December 2025, Captor Therapeutics reported last 12-month revenue of $5.4M and EBITDA of -$9.4M.

In the same period, Captor Therapeutics generated $4.6M in LTM gross profit and -$10.8M in net income.

See Captor Therapeutics valuation multiples based on analyst estimates

Captor Therapeutics P&L

In the most recent fiscal year, Captor Therapeutics reported revenue of $4.4M and EBITDA of -$9.2M.

Captor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Captor Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$5.4M	XXX	$4.4M	XXX	XXX	XXX
Gross Profit	$4.6M	XXX	$2.9M	XXX	XXX	XXX
Gross Margin	85%	XXX	67%	XXX	XXX	XXX
EBITDA	-$9.4M	XXX	-$9.2M	XXX	XXX	XXX
EBITDA Margin	-175%	XXX	-208%	XXX	XXX	XXX
EBIT	-$11.0M	XXX	-$10.8M	XXX	XXX	XXX
EBIT Margin	-204%	XXX	-246%	XXX	XXX	XXX
Net Profit	-$10.8M	XXX	-$10.7M	XXX	XXX	XXX
Net Margin	-201%	XXX	-243%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Captor Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $5.4M. EBITDA for the last twelve months was -$9.4M. In the most recent fiscal year, Captor Therapeutics achieved $4.4M in revenue and -$9.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$5.4M	Analyst estimates available to subscribers	$4.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$4.6M	Analyst estimates available to subscribers	$2.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	84.6% gross margin	Analyst estimates available to subscribers	67.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$9.4M	Analyst estimates available to subscribers	-$9.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-175.1% EBITDA margin	Analyst estimates available to subscribers	-208.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$11.0M	Analyst estimates available to subscribers	-$10.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-203.8% EBIT margin	Analyst estimates available to subscribers	-246.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$10.8M	Analyst estimates available to subscribers	-$10.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-200.5% net profit margin	Analyst estimates available to subscribers	-242.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Captor Therapeutics

This financial data table provides comprehensive performance metrics for Captor Therapeutics, a company based in Poland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Captor Therapeutics generated $5.4M in revenue over the last twelve months.
The company achieved -$9.4M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $4.6M.
Net income over the last twelve months reached -$10.8M.

Fiscal Year Performance

In the most recent fiscal year, Captor Therapeutics reported $4.4M in total revenue.
Fiscal year EBITDA was -$9.2M.
The company maintained a gross profit margin of 67.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -208.4%.
Net profit margin reached -242.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Captor Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Captor Therapeutics Stock Performance

Captor Therapeutics has current market cap of PLN 397M (or $110M), and EV of PLN 364M (or $101M).

Market Cap Evolution

Captor Therapeutics Stock Data

As of January 2, 2026, Captor Therapeutics's stock price is PLN 72 (or $20).

See Captor Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$101M	$110M	XXX	XXX	XXX	XXX	$-2.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Captor Therapeutics Valuation Multiples

Captor Therapeutics's trades at 19.0x EV/Revenue multiple, and -10.7x EV/EBITDA.

See valuation multiples for Captor Therapeutics and 15K+ public comps

Captor Therapeutics Financial Valuation Multiples

As of January 2, 2026, Captor Therapeutics has market cap of $110M and EV of $101M.

Equity research analysts estimate Captor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Captor Therapeutics has a P/E ratio of -10.2x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$110M	XXX	$110M	XXX	XXX	XXX
EV (current)	$101M	XXX	$101M	XXX	XXX	XXX
EV/Revenue	18.8x	XXX	19.0x	XXX	XXX	XXX
EV/EBITDA	-10.7x	XXX	-10.7x	XXX	XXX	XXX
EV/EBIT	-9.2x	XXX	-9.2x	XXX	XXX	XXX
EV/Gross Profit	22.2x	XXX	n/a	XXX	XXX	XXX
P/E	-10.2x	XXX	-10.2x	XXX	XXX	XXX
EV/FCF	-20.5x	XXX	-20.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Captor Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Captor Therapeutics Margins & Growth Rates

Captor Therapeutics's last 12 month revenue growth is 165%

Captor Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Captor Therapeutics's rule of 40 is -326% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Captor Therapeutics's rule of X is 237% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Captor Therapeutics and other 15K+ public comps

Captor Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	165%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	-175%	XXX	-178%	XXX	XXX	XXX
EBITDA Growth	-109%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-326%	XXX	-13%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	237%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	277%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	313%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial